肝癌是全球癌症相关死亡的主要原因之一，中国肝癌的全球负担占近一半。有效的干预措施如肝炎疫苗、新的血液检测和影像检测，在全球范围内，尤其是在中国，显著降低了发病率。揭示肝癌的系统和分子机制将有助于开发更有效的治疗方法，延长患者的5年生存期。中国的资助机构一直非常关注肝癌的基础和转化研究。在过去的十年中，中国国家自然科学基金委员会（NSFC）启动了一系列研究计划，支持了多个方向的肝癌研究。此外，肝癌领域在基础和临床研究、平台建设和药物开发方面取得了巨大进展。本文总结了中国的资助格局、研究进展、国家和机构之间的合作，以及药物发现方面的情况，并尝试与全球同行进行比较。版权所有 © 2023 Elsevier B.V. 出版。

Liver cancer is among the leading causes of cancer-related death worldwide and China accounts for nearly half of the global burden of liver cancer. Effective interventions such as hepatitis vaccinations, new blood tests and imaging tests significantly decreased the incidence worldwide, especially in China. Unraveling the systemic and molecular mechanisms of liver cancer would contribute to develop more effective therapies to prolong the 5 year survival of the patients. The Chinese funding agencies have been paying high attention to the basic and translational research of liver cancer. Over the last decade, the National Natural Science Foundation of China (NSFC) initiated a panel of research programs which supported liver cancer research in multiple directions. Besides, great progress has been made in basic and clinical research, platform construction and drug development in the field of liver cancer. In this article, we summarized the funding landscape, research progress, cooperation among countries and institutions, and drug discovery in China, with an attempt to compare the status and outcome with our peers globally.Copyright © 2023. Published by Elsevier B.V.